Floatz Rating
CCC51/100
Confidence
Indicative
Sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Modality
Small molecule
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
36High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03374852CT.gov CPI-613 in Combination With Modified FOLFIRINOX in Patients With Locally Advanced Pancreatic Cancer | — | Withdrawn | — | — | — |
NCT01839981CT.gov CPI-613 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer | — | Completed | — | — | — |
NCT01835041CT.gov CPI-613 and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Pancreatic Ductal Adenocarcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Devimistat (this asset) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | P2 | CCC · 51 |
| Rmc-6236 | Tango Therapeutics, Inc. | P3 | BB |
| Immunoglobulin G2, Anti-(Human Ctla-4 (Antigen)) (Human Monoclonal Cp-675206 Clone 11.2.1 Heavy Chain) Disulphide With Human Monoclonal Cp-675206 Clone 11.2.1 Light Chain, Dimer | OHSU Knight Cancer Institute | P2 | BB |
| Daraxonrasib | Revolution Medicines, Inc. | P3 | BB |
| S-1 | Genentech, Inc. | P2 | BB |
| Metformin | British Columbia Cancer Agency | P2 | BB |
| (R)-(1-(4-Fluorophenyl)-6-((1-Methyl-1H-Pyrazol-4-Yl)Sulfonyl)-1,4,5,6,7,8-Hexahydro-4Ah-Pyrazolo(3,4-G)Isoquinolin-4A-Yl)(4-(Trifluoromethyl)Pyridin-2-Yl)Methanone | Corcept Therapeutics | P3 | BB |
| Ivospemin | Panbela Therapeutics, Inc. | P2/3 | BB |
| Oxaliplatin | Jonsson Comprehensive Cancer Center | P4 | BB |
+42 more in the Pancreatic Ductal Adenocarcinoma cohort
Other indications for Devimistat
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Acute Myeloid Leukemia | — | P1/2 | CCC · 51 |
| Malignant Pancreatic Neoplasm | — | P2 | CCC · 51 |
| Exocrine Pancreatic Carcinoma | — | P2 | CCC · 51 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- Rmc-6236Tango Therapeutics, Inc.BB
- Immunoglobulin G2, Anti-(Human Ctla-4 (Antigen)) (Human Monoclonal Cp-675206 Clone 11.2.1 Heavy Chain) Disulphide With Human Monoclonal Cp-675206 Clone 11.2.1 Light Chain, DimerOHSU Knight Cancer InstituteBB
- DaraxonrasibRevolution Medicines, Inc.BB
- S-1Genentech, Inc.BB
- MetforminBritish Columbia Cancer AgencyBB
Citation
Floatz Terminal. Devimistat in Pancreatic Ductal Adenocarcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/devimistat-pancreatic-ductal-adenocarcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →